- Investing Ideas
- Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Results
6
Value score of at least 4 focused on companies with a low market cap.
6 companies
Cantargia
Market Cap: SEK 511.1m
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.
CANTA
SEK 2.06
7D
-29.5%
1Y
64.5%
Sprint Bioscience
Market Cap: SEK 369.3m
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
SPRINT
SEK 3.50
7D
-0.6%
1Y
733.3%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%
ODI Pharma
Market Cap: SEK 49.1m
A pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe.
ODI
SEK 2.68
7D
-29.5%
1Y
32.7%
Guard Therapeutics International
Market Cap: SEK 28.0m
A clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden.
GUARD
SEK 1.39
7D
-4.1%
1Y
-92.8%
Subgen AI
Market Cap: SEK 105.4m
Develops artificial intelligence-based models and applications to control data for government and businesses.
SUBGEN
SEK 0.10
7D
-23.9%
1Y
n/a